Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Apr;38(4):662–667. doi: 10.1128/aac.38.4.662

Clinical trial of ofloxacin alone and in combination with dapsone plus clofazimine for treatment of lepromatous leprosy.

B Ji 1, E G Perani 1, C Petinom 1, L N'Deli 1, J H Grosset 1
PMCID: PMC284522  PMID: 8031029

Abstract

Twenty-four patients with newly diagnosed lepromatous leprosy were allocated randomly to three groups and treated for 56 days with 400 mg of ofloxacin daily, 800 mg of ofloxacin daily, or 400 mg of ofloxacin, 100 mg of dapsone, and 50 mg of clofazimine daily plus 300 mg of clofazimine once every 28 days. The patients in all three groups demonstrated remarkable clinical improvements, accompanied by rapid decline of the morphological index in skin smears during treatment. More than 99, > 99.99, and > 99.99% of the viable Mycobacterium leprae organisms had been killed by 14, 28, and 56 days of treatment, respectively, as measured by inoculation into the footpads of immunocompetent and nude mice of organisms recovered from skin biopsy specimens obtained before and during treatment. Mild to moderate elevations of the serum glutamic pyruvic transaminase level were observed in four patients, all after 28 days of treatment, which returned to normal after the trial had been completed. Clinical improvement, bactericidal activity, and hepatotoxicity did not differ significantly among the three groups. Ofloxacin displayed powerful bactericidal activity against M. leprae in leprosy patients and may be an important component of new multidrug regimens for the treatment of leprosy. Its optimal dosage appears to be 400 mg daily, and combination with dapsone and clofazimine does not enhance its activity.

Full text

PDF
662

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Gelber R. H., Fukuda K., Byrd S., Murray L. P., Siu P., Tsang M., Rea T. H. A clinical trial of minocycline in lepromatous leprosy. BMJ. 1992 Jan 11;304(6819):91–92. doi: 10.1136/bmj.304.6819.91. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Grosset J. H., Guelpa-Lauras C. C., Perani E. G., Beoletto C. Activity of ofloxacin against Mycobacterium leprae in the mouse. Int J Lepr Other Mycobact Dis. 1988 Jun;56(2):259–264. [PubMed] [Google Scholar]
  3. Grosset J. H., Ji B. H., Guelpa-Lauras C. C., Perani E. G., N'Deli L. N. Clinical trial of pefloxacin and ofloxacin in the treatment of lepromatous leprosy. Int J Lepr Other Mycobact Dis. 1990 Jun;58(2):281–295. [PubMed] [Google Scholar]
  4. Halkin H. Adverse effects of the fluoroquinolones. Rev Infect Dis. 1988 Jan-Feb;10 (Suppl 1):S258–S261. doi: 10.1093/clinids/10.supplement_1.s258. [DOI] [PubMed] [Google Scholar]
  5. Ji B., Grosset J. H. Recent advances in the chemotherapy of leprosy. Lepr Rev. 1990 Dec;61(4):313–329. doi: 10.5935/0305-7518.19900029. [DOI] [PubMed] [Google Scholar]
  6. Ji B., Jamet P., Perani E. G., Bobin P., Grosset J. H. Powerful bactericidal activities of clarithromycin and minocycline against Mycobacterium leprae in lepromatous leprosy. J Infect Dis. 1993 Jul;168(1):188–190. doi: 10.1093/infdis/168.1.188. [DOI] [PubMed] [Google Scholar]
  7. N'Deli L., Guelpa-Lauras C. C., Perani E. G., Grosset J. H. Effectiveness of pefloxacin in the treatment of lepromatous leprosy. Int J Lepr Other Mycobact Dis. 1990 Mar;58(1):12–18. [PubMed] [Google Scholar]
  8. Shepard C. C. A brief review of experiences with short-term clinical trials monitored by mouse-foot-pad-inoculation. Lepr Rev. 1981 Dec;52(4):299–308. doi: 10.5935/0305-7518.19810040. [DOI] [PubMed] [Google Scholar]
  9. Shepard C. C., McRae D. H. A method for counting acid-fast bacteria. Int J Lepr Other Mycobact Dis. 1968 Jan-Mar;36(1):78–82. [PubMed] [Google Scholar]
  10. Shepard C. C. Statistical analysis of results obtained by two methods for testing drug activity against Mycobacterium leprae. Int J Lepr Other Mycobact Dis. 1982 Mar;50(1):96–101. [PubMed] [Google Scholar]
  11. Truffot-Pernot C., Ji B., Grosset J. Activities of pefloxacin and ofloxacin against mycobacteria: in vitro and mouse experiments. Tubercle. 1991 Mar;72(1):57–64. doi: 10.1016/0041-3879(91)90025-n. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES